Dapiglutide

DB19182InvestigationalProtein Based Therapies

Dapiglutide is under investigation in clinical trial NCT05788601 (Dapiglutide for the Treatment of Obesity).

Mechanism: Pharmacologically active on Glucagon-like peptide 1 receptor and Glucagon-like peptide 2 receptor
Curator reviewed
Also known as: Human glucagon like peptide-2 (glp-2) analogue; n6.16-(n-(17-carboxyheptadecanoyl)-l-.gamma.-glutamyl)- (a2>aib (2-methylalanine), d3>e, s7>t, d8>s, m10>l, n11>a, n16>k, l17>q, n24>a, t29>h)human glucagonlike peptide 2 (glp-2) · L-ASPARTIC ACID, L-HISTIDYL-2-METHYLALANYL-L-.ALPHA.-GLUTAMYLGLYCYL-L-SERYL-L-PHENYLALANYL-L-THREONYL-L-SERYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-ALANYL-L-THREONYL-L-ISOLEUCYL-L-LEUCYL-L-.ALPHA.-ASPARTYL-N6-(N-(17-CARBOXY-1-OXOHEPTADECYL)-L-.GAMMA.-GLUTAMYL)-L
Code names: ZP7570

Resolves to

Compound

Targets

What you can answer from here — as of July 09, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dapiglutide, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.